Related Experiment Video
Updated: Mar 18, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Paul T Kocis1, Guodong Liu2, Dinara Makenbaeva3
1Anticoagulation Clinic, Penn State Health, Milton S. Hershey Medical Center, Hershey, PA USA.
Insights
Most non-valvular atrial fibrillation (NVAF) patients take multiple daily medications, making once-daily anticoagulant choice less critical for convenience. This highlights the complexity of managing NVAF patients with numerous prescriptions.
Area of Science:
- Pharmacology
- Cardiology
- Health Services Research
Background:
- Drug administration frequency influences treatment choices.
- Non-valvular atrial fibrillation (NVAF) management involves complex medication regimens.
Purpose of the Study:
- To characterize NVAF patients and their chronic medication use patterns.
- To determine the proportion of NVAF patients taking non-anticoagulant medications more than once daily.
Main Methods:
- Analysis of a national health insurance claims database (2008-2011).
- Identification of NVAF patients and their prescription medication data.
- Evaluation of comorbidities and stroke risk scores (CHADS2, CHA2DS2-VASc).
Main Results:
- 324,172 NVAF patients included, with average CHADS2 (1.51) and CHA2DS2-VASc (3.08) scores.
- 92.5% of patients used chronic medications, averaging 6.9 per patient.
- 66.5% of all NVAF patients took medications more than once daily.
Conclusions:
- Chronic non-anticoagulant medication use is prevalent in NVAF patients.
- The majority of NVAF patients require multiple daily doses of non-anticoagulant medications.
- Convenience of once-daily anticoagulants may be less impactful given overall medication complexity.
Background:
Frequency of administration (once daily versus more than once daily) is believed to be an important consideration affecting drug choice.
Objective:
The aim of this study was to describe the characteristics of patients with non-valvular atrial fibrillation (NVAF) and the extent to which they take chronic medications, other than anticoagulants, more frequently than once daily.
Methods:
Using data from a large, national database of health insurance claims, patients with a diagnosis of NVAF between 1 July 2008 and 30 September 2011 were identified, along with their prescription medications, to determine the proportion of patients taking chronic medications more than once a day. Prescription medications, co-morbidities, and CHADS2 and CHA2DS2-VASc scores were evaluated. CHADS2 assesses the risk of stroke in NVAF patients with the following risk factors: Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, and history of prior Stroke or transient ischemic attack. The CHA2DS2-VASc score adds the following risk factors to the CHADS2 score: Age 65-74 years, Vascular Disease, and Sex Category (Female).
Results:
Overall, 324,172 patients with NVAF with mean CHADS2 and CHA2DS2-VASc scores of 1.51 and 3.08, respectively, were included in the study. Of these patients, 299,716 (92.5 %) took chronic medications, with an average of 6.9 medications per patient, and 215,527 (66.5 % of all patients or 71.9 % of those taking chronic medications) took medications more than once per day.
Conclusion:
Use of chronic medications other than anticoagulants is common among patients with NVAF, and medications are typically taken multiple times per day. The average number of medications per patient and multiple therapeutic classes prescribed underscore the clinical complexity of NVAF patients. Hence, the choice of a once daily anticoagulant versus a more than once daily anticoagulant may be less relevant in a real world NVAF population in terms of a potential convenience benefit.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias VI: Management of Dysrhythmias
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

